1Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 pa- tients. Ann Surg 1991; 214: 230-238; discussion 238-240.
2MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-alpha and interferon-gamma pro- duction measured at the single cell level in normal and in- flamed human intestine. Clin Exp Immunol 1990; 81:301-305.
3van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109:129-135.
4Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001; 345:1098-1104.
6Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Tha- lidomide selectively inhibits tumor necrosis factor alpha pro- duction by stimulated human monocytes. J Exp Med 1991; 173:699-703.
7Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn' s disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277.
8Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang H, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117:1278-1287.
9Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187:1885-1892.
10Fu LM, Fu-Liu CS. Thalidomide and tuberculosis. Int J Tu- berc Lung Dis 2002; 6:569-572.
